Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMD

26 Jul 2013

Abstract excerpt

PURPOSE: Exudative AMD (wet AMD) is treated by monthly injection into the eye of anti-VEGF proteins. VEGF is alternatively spliced to produce numerous isoforms that differ in angiogenic activity. Serine-rich protein kinase-1 (SRPK1) has been identified as a regulator of pro-angiogenic VEGF splicing by phosphorylating serine-rich splicing factor-1 (SRSF1), which binds to VEGF pre-mRNA. We tested the hypothesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis and VEGF in Cancer
Share to Retinal and Macular Surgery
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23887803
DOI: 10.1167/iovs.13-12422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Topical Antiangiogenic SRPK1 Inhibitors Reduce Choroidal Neovascularization in Rodent Models of Exudative AMDPMID 23887803Read ↗

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanomaSemantic proximity Read ↗

TAK1 blockade as a therapy for retinal neovascularizationSemantic proximity Read ↗

Splicing factor polymorphisms, the control of VEGF isoforms and association with angiogenic eye disease.Semantic proximity Read ↗

Suppression of Choroidal Neovascularization and Fibrosis by a Novel RNAi Therapeutic Agent against (Pro)renin ReceptorSemantic proximity Read ↗

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration: phase 1 and phase 2 trials in treatment-naïve and anti-VEGF pretreated patientsSemantic proximity Read ↗

Blockade of VEGFR1 and 2 Suppresses Pathological Angiogenesis and Vascular Leakage in the EyeSemantic proximity Read ↗

Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatmentSemantic proximity Read ↗

Gene therapy for ocular angiogenesisSemantic proximity Read ↗

Inhibition of Choroidal Neovascularization by Adenovirus-Mediated Delivery of Short Hairpin RNAs Targeting VEGF as a Potential Therapy for AMDSemantic proximity Read ↗

A novel retinoic acid drug, EYE-502, inhibits choroidal neovascularization by targeting endothelial cells and pericytesSemantic proximity Read ↗

Thrombospondin-1 proteomimetic polymers exhibit anti-angiogenic activity in a neovascular age-related macular degeneration mouse modelSemantic proximity Read ↗

Topical Administration of the Kappa Opioid Receptor Agonist Nalfurafine Suppresses Corneal Neovascularization and InflammationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.